Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-06-03Clinical Trial Update: VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial evaluating VEGF Trap (aflibercept) in patients with solid tumors or Non-Hodgkin's lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2016-06-03Clinical Trial Update: Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]
A Phase 1 trial update of intravenous aflibercept (VEGF trap) in patients with relapsed or refractory advanced solid tumors or non-Hodgkin l…
-
CLINICAL_TRIALS trial_result · 2016-06-03Clinical Trial Update: Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]
A Regeneron-sponsored Phase 1 trial evaluating intravenous aflibercept (VEGF trap) in patients with relapsed or refractory advanced solid tu…
-
CLINICAL_TRIALS trial_result · 2016-05-18Clinical Trial Update: Imaging Based Dosimetry for Individualized Internal Emitter Therapy
Completed trial evaluating imaging-based dosimetry to individualize internal emitter therapy for Non-Hodgkin's Lymphoma.
-
FDA approval · 2016-05-12FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for Mozobil (plerixafor) from Sanofi-Aventis U.S. LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-05-06Clinical Trial Update: Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma [Phase 1]
Phase 1 trial evaluating aflibercept in combination with standard R-CHOP chemotherapy in first-line non-Hodgkin B-cell lymphoma; the study s…
-
CLINICAL_TRIALS trial_result · 2016-05-05Clinical Trial Update: Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant
A Duke University registry study evaluating T-cell depleted allogeneic non-myeloablative stem cell transplantation for hematologic cancers h…
-
CLINICAL_TRIALS trial_result · 2016-05-02Clinical Trial Update: Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation [Phase 2]
Phase 2 clinical trial evaluating repeat transplantation for relapsed or refractory hematologic malignancies after prior transplant; the stu…
-
FDA approval · 2016-04-28FDA Approved: CARMUSTINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for Carmustine submitted by Heritage Pharmaceuticals Inc. (doing business as Avet Pharmaceutical…
-
CLINICAL_TRIALS research · 2016-04-20Clinical Trial Update: Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies [Phase 2]
Phase 2 clinical trial investigating thiotepa-based conditioning for allogeneic stem-cell transplantation in lymphoid malignancies, includin…
-
CLINICAL_TRIALS trial_result · 2016-04-20Clinical Trial Update: Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies [Phase 2]
Phase 2 trial evaluating treosulfan-based conditioning for allogeneic stem cell transplantation in lymphoid malignancies is being updated. T…
-
CLINICAL_TRIALS trial_result · 2016-04-04Clinical Trial Update: Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL) [Phase 2]
This document provides an update on a Phase 2 trial evaluating rituximab with CVP chemotherapy plus interferon for follicular non-Hodgkin ly…
-
CLINICAL_TRIALS trial_result · 2016-03-30Clinical Trial Update: Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating mobilization and collection of peripheral hematopoietic stem cells using Plerixafor plus G-CSF in Japanese patients…
-
CLINICAL_TRIALS trial_result · 2016-03-30Clinical Trial Update: A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating ocrelizumab in participants with follicular non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS research · 2016-03-30Clinical Trial Update: Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma [Phase 3]
This is a Phase 3 randomized trial comparing G-CSF alone versus intermediate-dose Ara-C plus G-CSF mobilization in patients with Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2016-03-15Clinical Trial Update: The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas [Phase 1]
A Phase 1 clinical trial evaluating the combination of everolimus (Rad001) and rituximab in patients with Non-Hodgkin lymphoma has completed…
-
CLINICAL_TRIALS trial_result · 2016-03-10Clinical Trial Update: Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 trial sponsored by the National Cancer Institute evaluated alisertib for relapsed or refractory peripheral T-cell non-Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2016-02-26Clinical Trial Update: Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating safety and efficacy of POL6326 for mobilization and transplant in hematologic malignancies has completed…
-
CLINICAL_TRIALS trial_result · 2016-02-26Clinical Trial Update: Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer [Phase 2]
Phase 2 trial update of Basiliximab to prevent graft-versus-host disease after nonmyeloablative allogeneic transplantation in blood cancers;…
-
CLINICAL_TRIALS trial_result · 2016-02-24Clinical Trial Update: Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release [Phase 2]
Phase 2 trial evaluating mesna to prevent doxorubicin-induced plasma protein oxidation and TNF-α release in patients with breast cancer or n…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
This ClinicalTrials.gov entry notes completion and posting of results for a trial evaluating rituximab in combination with CHOP or CHOP-like…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
A completed clinical trial update evaluating Ribomustin (bendamustine) as second-line therapy for relapsed or refractory indolent B-cell non…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial update evaluating Zevalin in combination with BuCyE high-dose therapy for B-cell non-Hodgkin lymphoma; the study status is c…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Gemcitabine for Marginal Zone Lymphoma [Phase 2]
A Phase 2 trial evaluating gemcitabine for marginal zone lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-02-15Clinical Trial Update: Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom [Phase 2]
A Phase 2 study evaluating transplantation using Zevalin (ibritumomab tiuxetan) with BEAM conditioning in patients with refractory diffuse l…